Get the Stockscreener App
0.9714
1.82%
0.0174
After Hours:
.95
-0.0214
-2.20%
Senti Biosciences Holdings Inc stock is traded at $0.9714, with a volume of 108.16K.
It is up +1.82% in the last 24 hours and up +6.50% over the past month.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
See More
Previous Close:
$0.954
Open:
$0.9502
24h Volume:
108.16K
Relative Volume:
0.67
Market Cap:
$30.25M
Revenue:
$22,000
Net Income/Loss:
$-61.44M
P/E Ratio:
-0.3042
EPS:
-3.1938
Net Cash Flow:
$-43.64M
1W Performance:
-1.26%
1M Performance:
+6.50%
6M Performance:
-46.33%
1Y Performance:
-70.56%
1-Day Range:
$0.9502
$0.9988
1-Week Range:
$0.8603
$1.04
52-Week Range:
$0.7702
$3.8844
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Holdings Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.9714 | 29.71M | 22,000 | -61.44M | -43.64M | -3.1938 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc Stock (SNTI) Latest News
Celadon backs Senti Biosciences (SNTI) with $40M notes and majority stake - Stock Titan
Senti Biosciences Secures Convertible Note Financing with Celadon - TipRanks
Senti Biosciences Holdings (NASDAQ: SNTI) continues $17.5M ATM program - Stock Titan
Senti Biosciences Strikes Up to $40 Million Secured Convertible Notes Financing With Celadon - TradingView
Celadon-led $40M notes could give Senti (NASDAQ: SNTI) majority holder - Stock Titan
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
Senti Biosciences 2025 Executive Compensation, Officer Employment Arrangements, and Stock Awards Overview - Minichart
[EFFECT] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences (NASDAQ: SNTI) files 10-K/A on 2025 pay, board and ownership - Stock Titan
Senti Biosciences Holdings, Inc.: Financial Data Forecasts Estimates and Expectations | SNTI | US8169441024 - marketscreener.com
Senti Biosciences (NASDAQ: SNTI) adopts S-3 post-merger reorganization - Stock Titan
Senti Biosciences Holdings (SNTI) adopts S-3 after April 24, 2026 merger - Stock Titan
Senti Biosciences completes holding company reorganization, stock continues on Nasdaq - Investing.com
Senti Biosciences (NASDAQ: SNTI) deregisters 8.7M shares previously for resale - Stock Titan
SNTI Senti Biosciences Inc. shares rise nearly 14 percent even as Q4 2025 EPS misses Wall Street estimates. - Cổng thông tin điện tử tỉnh Tây Ninh
Senti Biosciences (SNTI) Stock: Why You Should Avoid It (Bullish Sentiment) 2026-04-20Aggressive Growth Stocks - Xã Vĩnh Công
Senti Biosciences (SNTI) Stock 52-Week Low (Rocket Higher) 2026-04-18Community Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Senti Biosciences Q4 Operating Income USD -18 - Moomoo
[SCHEDULE 13D/A] Senti Biosciences, Inc. Amended Major Shareholder Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Bioscie - The National Law Review
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - Bitget
Cancer conference session will showcase Senti Bio's cell therapy approach - Stock Titan
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial - TradingView
Is Senti Biosciences (SNTI) Stock Trading at Fair Value | Price at $0.87, Up 1.55%Street Ratings - Cổng thông tin điện tử Tỉnh Sơn La
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
SNTI Q4 2025 Earnings: Senti Biosciences Inc. misses EPS estimates, no Q4 revenue - Newser
Senti Biosciences, Inc. Files Form 8-K Cover Report with NASDAQ Listing Details (April 1, 2026) - Minichart
Senti Biosciences plans holding company reorganization, stock to continue under SNTI - Investing.com India
Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026SEC Filing - TradingView
Senti Biosciences announces holding company reorganization effective by April 16, 2026SEC filing - marketscreener.com
Senti Biosciences Plans Tax-Free Holding Company Reorganization - TipRanks
Senti Biosciences, Inc. has filed documents with the U.S. Securities and Exchange Commission, officially announcing a holding company reorganization plan. - Bitget
Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI - TradingView — Track All Markets
Holding company reorg keeps Senti (NASDAQ: SNTI) stock structure intact - Stock Titan
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - Bitget
Senti Biosciences publishes CAR circuit research in Cell Systems - Investing.com
Senti Biosciences publishes CAR circuit research in Cell Systems By Investing.com - Investing.com India
Senti Biosciences (SNTI) holder NEA discloses 3.78M-share, 12.1% stake - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital - Defense World
SNTI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang - TipRanks
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Senti Biosciences, Inc. (SNTI) Reports Q4 Earnings - AlphaStreet
Senti Biosciences stock rating held at Buy by H.C. Wainwright - Investing.com Canada
Senti Biosciences stock rating held at Buy by H.C. Wainwright By Investing.com - Investing.com India
Senti Biosciences (NASDAQ: SNTI) advances SENTI-202 gene circuit CAR-NK program - Stock Titan
Senti Biosciences 10-K: Collaboration revenue $0.022M, Net loss $61.44M, EPS $(2.73) - TradingView
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Senti Biosciences Q4 revenue misses analyst estimates - tradingview.com
SNTI: Positive SENTI-202 clinical progress, RMAT status, and $61.4M net loss with $16.4M cash - TradingView
Senti Bio (NASDAQ: SNTI) posts 2025 loss as SENTI-202 gains FDA RMAT - Stock Titan
Senti Biosciences Holdings Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):